Intellia Therapeutics earnings were -$508.8M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest NTLA earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$147.0M, up 36.8% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, NTLA reported annual earnings of -$481.2M, with 1.5% growth. The next NTLA earnings date is Nov 7, 2024.
Intellia Therapeutics Earnings Reports & History FAQ
What were Intellia Therapeutics's earnings last quarter?
On NTLA's earnings call on Invalid Date, Intellia Therapeutics (NASDAQ: NTLA) reported Q2 2024 earnings per share (EPS) of -$1.52, up 8.57% year over year. Total NTLA earnings for the quarter were -$146.98 million. In the same quarter last year, Intellia Therapeutics's earnings per share (EPS) was -$1.40.
The next NTLA earnings call is Invalid Date. Add NTLA to your watchlist to be reminded of Intellia Therapeutics's next earnings date.
Is Intellia Therapeutics profitable or losing money?
As of the last Intellia Therapeutics earnings report, Intellia Therapeutics is currently losing money. Intellia Therapeutics's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$508.80 million, a 12.21% increase year over year.
What was NTLA's earnings growth in the past year?
As of Intellia Therapeutics's earnings date in Invalid Date, Intellia Therapeutics's earnings has grown year over year. NTLA earnings in the past year totalled -$508.80 million.
What are Intellia Therapeutics's earnings expectations?
The current EPS estimate for Intellia Therapeutics's earnings report in Invalid Date is -$1.39.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.